Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Moodys
Dow
McKesson
Express Scripts

Last Updated: November 15, 2019

DrugPatentWatch Database Preview

IDHIFA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Idhifa, and when can generic versions of Idhifa launch?

Idhifa is a drug marketed by Celgene Corp and is included in one NDA. There are five patents protecting this drug.

This drug has seventy-five patent family members in thirty-four countries.

The generic ingredient in IDHIFA is enasidenib mesylate. One supplier is listed for this compound. Additional details are available on the enasidenib mesylate profile page.

Summary for IDHIFA
Drug patent expirations by year for IDHIFA
Drug Prices for IDHIFA

See drug prices for IDHIFA

Generic Entry Opportunity Date for IDHIFA
Generic Entry Date for IDHIFA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IDHIFA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AbbViePhase 1/Phase 2
CelgenePhase 1/Phase 2
University Health Network, TorontoPhase 1/Phase 2

See all IDHIFA clinical trials

Pharmacology for IDHIFA
Synonyms for IDHIFA
1446502-11-9
2-methyl-1-((4-(6-(trifluoromethyl)pyridin-2-yl)-6-((2-(trifluoromethyl)pyridin-4-yl)amino)-1,3,5-triazin-2-yl)amino)propan-2-ol
2-Methyl-1-(4-(6-(trifluoromethyl)pyridin-2-yl)-6-(2-(trifluoromethyl)pyridin-4-ylamino)-1,3,5-triazin-2-ylamino)propan-2-ol
2-Methyl-1-[(4-[6-(Trifluoromethyl)pyridin-2-Yl]-6-{[2-(Trifluoromethyl)pyridin-4-Yl]amino}-1,3,5-Triazin-2-Yl)amino]propan-2-Ol
2-methyl-1-[[4-[6-(trifluoromethyl)pyridin-2-yl]-6-[[2-(trifluoromethyl)pyridin-4-yl]amino]-1,3,5-triazin-2-yl]amino]propan-2-ol
2-Propanol, 2-methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-
3T1SS4E7AG
69Q
AG 221
AG-221
AG-221 (Enasidenib)
AG-221; Enasidenib
AG-221(Enasidenib)
AG221
AKOS026750439
BCP16041
CC 90007
CC-90007
CC-90007 Free Base
CC90007
CHEMBL3989908
CS-5017
D10901
DB13874
Enasidenib
Enasidenib (USAN/INN)
Enasidenib [INN]
Enasidenib [USAN:INN]
Enasidenib mesylate
EX-A654
FT-0700204
GTPL8960
HY-18690
J-690181
KB-3356927
KS-000006AW
NCGC00479249-03
NCGC00479249-05
s8205
SB19193
SCHEMBL15102202
UNII-3T1SS4E7AG
ZINC222731806

US Patents and Regulatory Information for IDHIFA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No   Start Trial   Start Trial   Start Trial
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Express Scripts
Harvard Business School
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.